SCHEMBL6445449

SCHEMBL6445449

CS(=O)(=O)NC(=O)c1cccc2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.48
CYP2C19 P33261 5/20 0.46
CYP2D6 P10635 4/20 0.46
CYP3A4 P08684 3/20 0.43
RAB9A P51151 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C8 P10632 1/20 0.42
CYP2B6 P20813 1/20 0.42
KCNH2 Q12809 1/20 0.42
POLB P06746 1/20 0.42
ALOX5 P09917 1/20 0.41
MMP2 P08253 1/20 0.41
MMP13 P45452 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441130 0.89 CYP2C9 (0.45) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL11982163 0.85 CYP2C9 (0.48) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL6445201 0.84 CYP2C9 (0.53) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL6442977 0.84 CYP2C9 (0.50) CYP2C9CYP2C19CYP2D6CYP3A4CYP1A2
SCHEMBL11982243 0.80 CYP2C9 (0.48) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL10266759 0.79 CYP2C9 (0.54) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL11982265 0.79 CYP2C9 (0.47) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL11982194 0.79 CYP2C9 (0.50) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL11982324 0.77 CYP2C9 (0.50) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A
SCHEMBL11982335 0.77 CYP2C9 (0.53) CYP2C9CYP2C19CYP2D6CYP3A4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
EP-1299382-A4 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2004-02-11 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed
EP-1299382-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-09 EP claimed
WO-2002004440-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA CYP2C9 2370/4885CYP2C19 1624/4885CYP2D6 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.